EPISODE · Apr 15, 2026 · 7 MIN
hVIVO: beating the odds in 2025 - and why 2026 looks better still
from Proactive - Interviews for investors · host Proactive Investors
hVIVO PLC (AIM:HVO) CEO Yamin 'Mo' Khan joined Proactive's Stephen Gunnion to discuss the company's full-year 2025 results, which showed financial resilience despite a tough macro environment. Revenue came in at just under £47 million, in line with expectations, while EBITDA of just over £1 million beat earlier guidance of a small loss, driven by strong cost discipline, cancellation fees, and a solid Q4. The company closed the year with over £14 million in cash. Strategically, hVIVO made meaningful progress on diversification. Acquisitions, including clinical trial units in Germany and UK-based CryoStore, have broadened its capabilities, and the business is now consolidating under a single brand across four integrated service lines: human challenge trials, clinical trials, laboratory services, and consulting. Khan described the platform as giving access to "many more clients." Although the human challenge trial segment faced headwinds from vaccine market volatility in 2025, proposal activity has picked up sharply in early 2026. The company is guiding for high single-digit revenue growth this year, underpinned by a growing pipeline and a new partnership with Traws Pharma. For more insights like this, visit Proactive’s YouTube channel, like this video, subscribe, and enable notifications so you never miss an update. #hVIVO #ClinicalTrials #Biotech #Pharma #HealthcareInvesting #LifeSciences #EarningsReport #BiotechNews #ClinicalResearch #DrugDevelopment #InvestingNews #SmallCapStocks #HealthcareInnovation #PharmaIndustry #MarketUpdate
What this episode covers
hVIVO PLC (AIM:HVO) CEO Yamin 'Mo' Khan joined Proactive's Stephen Gunnion to discuss the company's full-year 2025 results, which showed financial resilience despite a tough macro environment. Revenue came in at just under £47 million, in line with expectations, while EBITDA of just over £1 million beat earlier guidance of a small loss, driven by strong cost discipline, cancellation fees, and a solid Q4. The company closed the year with over £14 million in cash. Strategically, hVIVO made meaningful progress on diversification. Acquisitions, including clinical trial units in Germany and UK-based CryoStore, have broadened its capabilities, and the business is now consolidating under a single brand across four integrated service lines: human challenge trials, clinical trials, laboratory services, and consulting. Khan described the platform as giving access to "many more clients." Although the human challenge trial segment faced headwinds from vaccine market volatility in 2025, proposal activity has picked up sharply in early 2026. The company is guiding for high single-digit revenue growth this year, underpinned by a growing pipeline and a new partnership with Traws Pharma. For more insights like this, visit Proactive’s YouTube channel, like this video, subscribe, and enable notifications so you never miss an update. #hVIVO #ClinicalTrials #Biotech #Pharma #HealthcareInvesting #LifeSciences #EarningsReport #BiotechNews #ClinicalResearch #DrugDevelopment #InvestingNews #SmallCapStocks #HealthcareInnovation #PharmaIndustry #MarketUpdate
NOW PLAYING
hVIVO: beating the odds in 2025 - and why 2026 looks better still
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.